A retrospective evaluation of lomustine (CeeNU) in 32 treatment naïve cats with intermediate to large cell gastrointestinal lymphoma (2006–2013)

Multi‐drug chemotherapy protocols for feline lymphoma have demonstrated variable efficacy and tolerability. In phase I trials, lomustine has demonstrated efficacy for cats with lymphoma though its use for treatment naïve feline intermediate/large cell gastrointestinal (GI) lymphoma remains unknown....

Full description

Saved in:
Bibliographic Details
Published in:Veterinary & comparative oncology 2017-09, Vol.15 (3), p.1019-1028
Main Authors: Rau, S. E., Burgess, K. E.
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents, Alkylating - therapeutic use
Cat Diseases - drug therapy
Cats
feline
Female
gastrointestinal
Gastrointestinal Neoplasms - drug therapy
Gastrointestinal Neoplasms - veterinary
lomustine
Lomustine - therapeutic use
lymphoma
Lymphoma - drug therapy
Lymphoma - veterinary
Male
Retrospective Studies
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multi‐drug chemotherapy protocols for feline lymphoma have demonstrated variable efficacy and tolerability. In phase I trials, lomustine has demonstrated efficacy for cats with lymphoma though its use for treatment naïve feline intermediate/large cell gastrointestinal (GI) lymphoma remains unknown. This study evaluated the efficacy and tolerability of lomustine for the treatment of feline GI lymphoma. Thirty‐two cats with histologically or cytologically confirmed intermediate/large cell GI lymphoma were evaluated retrospectively. Factors assessed included clinical signs, hematologic/biochemical parameters and use of l‐asparaginase at induction. A response rate of 50% (16/32), with median duration of response of 302 days (range 64–1450 days), was found. Median progression‐free interval was 132 days (range 31–1450 days), with overall median survival time of 108 days (range 4–1488 days). History of hyporexia, presence of anaemia and dose of lomustine were significantly associated with progression‐free survival. Overall, lomustine is a well‐tolerated and effective treatment for feline GI lymphoma.
ISSN:1476-5810
1476-5829
DOI:10.1111/vco.12243